ONCIMMUNE LEADING EARLY CANCER DETECTION
 
ONCIMMUNE LEADING EARLY CANCER DETECTION

Lung cancer screening with CT scans is leading to a significant increase in the number of patients diagnosed with lung nodules

  • Over 95% of positive CT scans are false positives, i.e. not cancer
  • About 50% of larger CT detected nodules are Intermediate1 risk level (10-65% risk, circa 8mm to 20mm in diameter)

EarlyCDT-Lung significantly aids the assessment of malignancy risk in pulmonary nodules

  • A positive EarlyCDT-Lung result can be used to ‘rule-in’ lung nodules as malignant: nearly 4 out of 5 positive results are a true cancer with a High Level result, and 1 in 1.7 for a Moderate Level result
  • EarlyCDT-Lung can help reduce the number of patients in ‘watchful waiting’ and aid early lung cancer detection, leading to earlier intervention and better patient outcomes
  • A High Level EarlyCDT-Lung result has high Specificity (98%), PPV > 78% and Accuracy 84% in patients with nodules2
  • A Moderate Level EarlyCDT-Lung result also has high Specificity (93%), PPV 59% and Accuracy 83%2
  • A High Level EarlyCDT-Lung result shifts all Intermediate Risk level (10-65%, circa 8-20mm in diameter) nodules to Intervention1 risk (>65%)
  • A ‘Moderate Level’ EarlyCDT-Lung result adds more than 25% to the calculated malignancy risk of a nodule, shifting some nodules from Intermediate to Intervention1 risk level
  • A ‘No Significant Level of Autoantibodies Detected’ EarlyCDT-Lung result should not change the clinical management of lung nodules

EarlyCDT-Lung significantly improves Positive Predictive value (PPV) for the assessment of risk of lung nodule malignancy3

1Gould MK, et al. Evaluation of individuals with pulmonary nodules: when is it lung cancer? Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2013; 143(5):e93S-e120S, https://www.ncbi.nlm.nih.gov/pubmed/23649456
2 Based on lung cancer prevalence of 20%
3 Massion PP, Healey GF, Peek LJ, Fredericks L, Sewell HF, Murray A, Robertson JF. Autoantibody Signature Enhances the Positive Predictive Power of Computed Tomography and Nodule-Based Risk Models for Detection of Lung Cancer. J Thorac Oncol. 2017 Mar;12(3):578-584. doi: 10.1016/j.jtho.2016.08.143. Epub 2016 Sep 8

PLEASE READ THE FOLLOWING STATEMENT CAREFULLY

Electronic versions of the materials you are seeking to access are being made available on this website by Oncimmune Holdings plc (the “Company”).

These materials are not directed to nor are they intended for access by persons located or resident in the United States, Australia, Canada, South Africa, Japan or any other jurisdiction where to do so would constitute a violation of the relevant laws or regulations of such jurisdiction.

None of the securities of Company discussed or referred to in the materials you are seeking to access have been registered under the US Securities Act or 1933, as amended (the “Securities Act”) and may not be offered, sold, pledged or otherwise transferred except (1) in an offshore transaction meeting the requirements of Rule 903 or Rule 904 of Regulation S under the Securities Act, (2) pursuant to an effective registration statement under the Securities Act, or (3) pursuant to an available exemption from the registration requirements of the Securities Act, in each case in accordance with all applicable securities laws.

By clicking the “SUBMIT” button below you confirm that you (1) have read and understood the information set out above, (2) agree to be bound by its terms, (3) are not located in the United States and do not have a registered address in, and are not resident or located in, Australia, Canada, South Africa or Japan and (4) are permitted under applicable law and regulation to proceed to the following parts of this website.

Please click on the button below to confirm that you have read, understood and agree with the disclaimer above.

Yes, I accept No, I don't accept